Prandoni and colleagues (1) reported that residual venous thrombosis was an important risk factor for recurrent thromboembolism. The high incidence of persistent abnormalities on venous ultrasonography after 3 months of anticoagulation for initial deep venous thrombosis (DVT) has been previously noted (2, 3), but the reasons for this lack of resolution remain unclear. Because the authors did not report any specific data on international normalized ratios (INRs) or the length of time that the INRs remained in the therapeutic range during the initial course of anticoagulation, it is possible that such treatment variables might explain the high incidence of residual abnormalities noted on follow-up ultrasonography. Caprini and associates (4) reported that patients with incomplete DVT resolution after 6 months of warfarin treatment had median INRs that were significantly lower than the INRs of patients who demonstrated complete thrombus resolution. We believe that strict maintenance of the INR within the therapeutic range might increase the rate of complete DVT resolution and thereby lessen the subsequent risk for recurrent thromboembolism.
TO THE EDITOR:
The article by Prandoni and colleagues (1) showed an association between residual venous thrombosis and recurrent venous thromboembolism. As demonstrated in several studies, DVT appears to be multifactorial (2) . Therefore, the authors' classification of patients is confusing. They divided patients into three main categories: thrombophilia, secondary thrombosis, and idiopathic thrombosis. This does not take into consideration the fact that in thrombophilia, a triggering event (for example, secondary thrombosis) often contributes to the disease (3) . Furthermore, 15% of Prandoni and colleagues' patients were not tested for thrombophilia. It would be useful for the medical community and ongoing or future studies to adopt a consensus classification for the description of the subpopulations; this would allow us to extrapolate results from one study to another.
The authors demonstrated an association between residual thrombosis and recurrence, but they also nicely showed that the rate of venous sequelae decreased over time, from 60% at 6 months to less than 30% at 36 months. On the other hand, the rate of recurrence also decreased with time, mainly after the first 24 months following the acute event. These observations, together with the fact that most recurrences affect the contralateral leg (without sequelae), suggest that residual thrombosis itself is probably not a major cause of thrombosis. Prandoni and colleagues suggested that their results are widely generalizable, but the interesting association they reported should first be confirmed in other studies. Finally, sequelae were assessed only by venous compression, but pulsed Doppler echocardiography for reflux was not done. It would be of interest to demonstrate that complete or partial obstruction of a vein is worse than major reflux, which induces stasis. However, this last evaluation is probably not as easy and reproducible as vein compression. In the article by Prandoni and colleagues (1), veins were considered recanalized if they measured 3.0 mm or less in diameter during a 6-year period. However, in a previous study of 1017 patients, it was very unusual to observe a diameter less than 5 mm in cases of DVT (2), and 5 mm was proposed as the minimum threshold value for diagnosis of thrombus (2). Meissner and associates (3) studied patients with unilateral thrombosis and found that segments with residual disease were 0.07 to 0.28 cm smaller than those on the contralateral disease-free side. In addition, the diameter index (ipsilateral-contralateral diameter) was significantly lower in patients with unilateral thrombosis than in normal patients. At the end of 6 months, recanalized segments did not differ significantly from those on the contralateral side, and diameter indices in patients with unilateral thrombosis and in normal patients were indistinguishable (3 We agree with Drs. Emmerich and Fiessinger that the assessment of venous reflux is much less reproducible than compression ultrasonography. We also agree that our results need confirmation before implementation in daily routine, since prognostic associations do not necessarily translate into causal relationships. However, it should be noted that our results are fully consistent with the recent results of a study by another group (1) . The observation that patients with residual venous thrombosis are as likely to develop ipsilateral as contralateral venous thrombosis suggests that residual venous thrombosis is not the cause in itself but is merely a marker (as a result of underlying hypercoagulability?) for subsequent venous thromboembolism. Indeed, it would be ideal to widely adopt a consensus classification for the description of the various subpopulations in venous thrombosis, but we view this as a difficult task to achieve because of the ongoing evolution of insights in etiology and pathogenesis.
To Dr. Rajput, we would like to reiterate that our study did not evaluate the compressed vein diameters at presentation of the acute episode but reported on the presence of residual thrombosis after months of anticoagulation and its association with subsequent recurrent venous thromboembolism. 
Paolo Prandoni, MD, PhD

Use of ␤-Blockers in Patients with Reactive Airway Disease
TO THE EDITOR:
We are very concerned about the conclusions of Salpeter and colleagues' meta-analysis on cardioselective ␤-blockers in patients with reactive airway disease (1). With reactive airway disease, the immediate drop in FEV 1 may not indicate the risk to patients taking ␤-blocking medications. In the 10 continued treatment studies, only 141 participants received ␤-blockers for 3 days to 4 weeks. Individuals with mild to moderate asthma may tolerate ␤-blockade well between asthma triggers. Long-term studies (Ն1 year) must be performed to examine the frequency of asthma exacerbations and steroid burst, as well as hospitalization and death rates, before the true safety of ␤-blockade can be ascertained. Most persons with reactive airway disease can tolerate a substantial degree of airway obstruction until challenged with exercise, a viral respiratory infection, or an allergen exposure. We disagree with Dr. Epstein's editorial (2), which states that Salpeter and colleagues' meta-analysis proves the safety of ␤-blockade in persons with mild to moderate asthma. Salpeter and colleagues' findings do suggest that many persons with mild to moderate asthma can receive ␤-blockade for a relatively short time, but the question of safety over the long term has not been answered. : We agree that further study of the long-term effects of ␤-blockers in patients with reactive airway disease is needed. Our study demonstrated the safety of cardioselective ␤-blockers in patients with mild to moderate reactive airway disease who were followed for up to 4 weeks. We believe that this study paves the way for larger, long-term trials to be done. In the meta-analysis, patients who received a single dose or continued treatment with a cardioselective ␤-blocker had an increased FEV 1 response to ␤-agonists compared with placebo. Furthermore, in the continued treatment trials, steroid use, asthma exacerbations, and hospitalizations did not increase.
We remind readers that the evidence for the benefit of ␤-blockers in conditions such as acute myocardial infarction, coronary artery disease, diabetes mellitus, and congestive heart failure, as well as in the perioperative period, is convincing and strong. Our analysis, which pooled results from 29 randomized, controlled trials, indicated that ␤-blocker use should not be withheld from patients with a history of reactive airway disease. We hope our study will encourage more widespread use of cardioselective ␤-blockers in patients who could benefit from them. 
IN RESPONSE: We appreciate Dr. Jackson's interest in our article and will address his questions with pleasure. First, with regard to the role of sentinel lymph node biopsy in men, limited data are available. Several case reports of sentinel node biopsies performed in men have been published (1) . However, the correlation between sentinel node biopsy and standard axillary dissection has not been established in men. We recognize that the rarity of male breast cancer makes the collection of a sufficient number of cases difficult, and thus it may not be possible to conclusively answer this question. Given that we would not expect a difference in the accuracy of this procedure by sex, sentinel node biopsy is a reasonable, although unproven, approach.
In answer to the second question, we would not recommend positron emission tomography or bone marrow aspiration as tools to decide whether a patient with early-stage disease should undergo adjuvant therapy. We do not routinely use these tests to determine whether women will benefit from adjuvant chemotherapy and are aware of no data to support their routine use in men with breast cancer.
The third question inquires about the relationship between adjuvant tamoxifen and the risk for prostate cancer. Tamoxifen is a selective estrogen receptor modulator (SERM) that has both estrogenic and antiestrogenic properties and appears to have some activity against prostate cancer. Tamoxifen and raloxifene (another SERM) have been shown to induce apoptosis in human prostate cancer cell lines (2, 3). However, in clinical trials, tamoxifen has had only limited activity in treating metastatic androgen-independent prostate cancer. Whether tamoxifen is effective as a chemopreventive agent for prostate cancer is unclear. In a rat model, tamoxifen prevented cancer of the seminal vesicle and prostate (4) . Because of the promising results in animal models, a phase II clinical trial using another SERM (GTx-006) for chemoprevention of prostate cancer is under way (5). We will have to await the results of this and other clinical trials and epidemiologic studies to definitively answer this question. 
Advancing the War on Malaria
TO THE EDITOR: Jennifer Fisher Wilson's article "Advancing the War on Malaria" (1) comprehensively reviews current understanding of the disease. We agree with her that "science often fails to deliver to the poor even existing, simple solutions." This is certainly the case in sub-Saharan Africa. However, Ms. Wilson understated the role of insecticide-treated nets (ITNs). Evidence for the effectiveness of ITNs has been accumulating for two decades. A Cochrane review concluded that ITNs reduce overall mortality by 20% in Africa and that among 1000 children younger than 5 years of age who are protected, 6 lives can be saved per year (2) . Described as one of the most effective child-survival strategies ever devised, matched only by measles vaccine and oral rehydration fluids (3), ITNs, like vaccines, offer both personal protection to the individual user and a community-wide "mass" effect.
With the efficacy of ITNs in Africa firmly established, we agree with Ms. Wilson that the challenge is to find systems for delivering these valuable tools to the most needy. Strategies used by ministries, agencies, and projects in recent years have been diverse, resulting in a wealth of evidence and lessons learned. Among its many achievements, the World Health Organization's Roll Back Malaria partnership developed an initiative called Scaling-Up Insecticide-Treated Netting Programmes in Africa: A Strategic Framework for Coordinated National Action (4). The framework addresses the need for an effective, affordable, and sustainable strategy that combines public provision of targeted subsidies to maximize public health benefits with support and stimulation of the commercial market. It is unrealistic to believe that the resource level required to sustain effective coverage for all those in need can be maintained by philanthropy alone. It makes sense to exploit and develop local production and commercial distribution of ITNs. Policy decisions leading to both effectiveness and sustainability need to be evidence-based. There is an urgent need for the operational research that will provide such evidence. 
CLINICAL OBSERVATION
Treatment of Severe Pulmonary Hypertension with Inhaled Iloprost
TO THE EDITOR:
We report successful treatment of severe pulmonary hypertension with inhaled aerosolized iloprost in a patient with Gaucher disease, a lysosomal storage disorder (1-4) . A 39-year-old woman with underlying adult Gaucher disease was admitted to our hospital with exertional dyspnea that markedly limited her physical activity (New York Heart Association class III). She had received a diagnosis of type I Gaucher disease at the age of 12 years and had been treated with enzyme replacement therapy (imiglucerase). On presentation, she was able to walk 500 m in 6 minutes. During cycle spiroergometry with a working rate of 60 W, she reached a peak oxygen uptake (VO 2 ) of 15.1 mL/kg per minute. Brain natriuretic peptid levels were increased 10-fold. Initial rightheart catheterization showed severe precapillary pulmonary hypertension with pulmonary vascular resistance of 1506 dynes/s ⅐ cm Ϫ5 , mean pulmonary artery pressure of 61 mm Hg, and cardiac output of 2.71 L/min. Acute testing with inhaled iloprost showed substantial reduction in pulmonary vascular resistance (32%). The patient received oral anticoagulant therapy and was treated with inhaled iloprost, 100 g/d, for 9 months.
After 3 months, repeated right-heart catheterization showed markedly improved hemodynamic characteristics at trough level (pulmonary vascular resistance, 695 dynes/s ⅐ cm Ϫ5 ; pulmonary artery pressure, 42 mm Hg; cardiac output, 4.25 L/min). Pulmonary vascular resistance decreased further (21%) during inhalation of iloprost. The patient's New York Heart Association class improved to II after 6 weeks of iloprost treatment and to I after 9 months of treatment. Distance in the 6-minute walk improved to 600 m after 6 weeks of therapy and 650 m after 9 months of therapy. Peak VO 2 increased to 17.1 mL/kg per minute with a working rate of 80 W after 6 weeks and to 19.1 mL/kg per minute after 3 months. After 6 months, peak VO 2 reached 20.8 mL/kg per minute at a working rate of 100 W. In addition, brain natriuretic peptid levels normalized after 6 months. On the basis of these results, we suggest that inhaled iloprost should be considered for treatment of pulmonary hypertension associated with Gaucher disease. : We read the paper by Krantz and colleagues (1) about torsades de pointes in patients treated with methadone. In our hospital, four HIV-infected patients receiving methadone therapy presented with episodes of syncope. All of them had a prolongation of the corrected QT interval (QTc) (Ͻ0.45 seconds) and several episodes of torsades de pointes. All of the patients were men, and the mean age was 35 years. When the syncope occurred, two patients had AIDS and three were taking antiretroviral therapy with reverse transcriptase inhibitors. The mean daily methadone dose was 365 mg (range, 275 to 500 mg), and the mean QTc interval was 0.59 seconds (range, 0.51 to 0.64 seconds). Three patients had mild echocardiographic abnormalities, namely ventricular dilatation and hypokinetic areas; two had ionic disorders (potassium level, 2.9 mmol/L; ionized calcium level, 0.95 mmol/L [3.8 mg/dL]); and three were simultaneously taking potentially arrhythmogenic drugs (clarithromycin, foscarnet, and cotrimoxazole). Furthermore, we cannot rule out the possibility that these patients were adult carriers of a silent genetic anomaly. We were able to reduce the methadone dose in three of four patients and, of interest, observed a shortening of the QT interval. The resulting mean QTc interval was 0.47 second (range, 0.38 to 0.57 second).
H.H. Leuchte, MD
The long QT syndrome related to viral cardiomyopathies or autonomous neuropathies has been described in HIV-infected patients (2, 3) but is usually related to drugs (macrolides, quinolones, clindamycin, trimethoprim-sulfamethoxazole, fluconazole, foscarnet, and pentamidine). Methadone affects several variables of cardiac function and has a negative inotropic and chronotropic effect in vitro (4) . Antiretroviral therapy increases drug interactions by the inhibition and induction of cytochrome P450, and higher doses of methadone are used when the drug is given with non-nucleoside reverse transcriptase inhibitors.
Although all of our patients had nonpharmacologic factors that may potentially prolong the QT interval, the sequence of events suggests that methadone caused the prolongation and provided the substrate for torsades de pointes.
Montserrat Sala, MD Ignasi Anguera, MD Manuel Cervantes, MD Institut Universitari Parc Taulí, Hospital de Sabadell 08208 Sabadell, Barcelona, Spain TO THE EDITOR: Krantz and colleagues (1) did an exceptional job in analyzing a possible association between very high doses of methadone and torsades de pointes. We report the case of a 41-year-old woman admitted to the hospital for syncope. During initial evaluation in the emergency department, the patient was found to have torsades de pointes. The QTc interval was found to be 550 milliseconds (2). The patient had no family history of arrhythmias. Potassium level was 3.6 mmol/L, and magnesium level was 0.62 mmol/L. A urine drug screening test was positive for methadone. The patient eventually had echocardiography, which showed no structural heart disease, and cardiac catheterization, which confirmed that her coronary arteries were normal. She subsequently had a defibrillator implanted and was discharged.
We certainly feel that there is an association between methadone use and torsades de pointes (3). However, like Krantz and colleagues, we were unable to rule out congenital prolonged QT interval (4) . Also, we could not confirm the actual dosage of methadone the patient was receiving before her arrhythmia, since she was obtaining methadone from her significant other and was not enrolled in a treatment program. 
